Latigo Biotherapeutics Inc.

LTGO

NASDAQHealthcareMedical - Pharmaceuticals

在 GoAI 中打開

前收盤價

US$22.55

−US$1.38 · -5.77%

9月18日下午4:00 ET

公司概況

公司網站

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

產業: Medical - Pharmaceuticals
部門: Healthcare
總部: US
執行長: Nima Farzan
上市以來: 2026年8月7日
僱員: 59

市場位置

日內區間

目前US$22.55

US$22.21US$24.50

52週區間

目前US$22.55

US$17.22US$25.93

開盤價: US$24.18
前收盤價: US$23.93
成交量: 148.82萬; 4.03× 平均值
平均成交量: 36.96萬; 日均成交量
市值: 13.56億 USD
貝塔: 0; 市場參考 1
50天平均值: US$21.7727; 高於平均水平+3.57%
200天平均值: US$21.7727; 高於平均水平+3.57%

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$52.25

上漲空間 131.71%

過去 12 個月12個月預測最高：US$73.00平均的：US$52.25最低：US$36.00

LTGO 訊息

defenseworld.net2026年9月9日

Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)

Latigo Biotherapeutics' (NASDAQ: LTGO - Get Free Report) quiet period will expire on Wednesday, September 16th. Latigo Biotherapeutics had issued 19,200,000 shares in its public offering on August 7th. The total size of…

閱讀原始碼

globenewswire.com2026年9月3日

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund…

閱讀原始碼

247wallst.com2026年8月13日

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about.

閱讀原始碼

defenseworld.net2026年8月11日

Latigo Biotherapeutics (NASDAQ:LTGO) Director James Tananbaum Buys 140,000 Shares

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) Director James Tananbaum bought 140,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an…

閱讀原始碼

defenseworld.net2026年8月11日

Latigo Biotherapeutics (NASDAQ:LTGO) Major Shareholder Foresite Capital Management V, Acquires 140,000 Shares

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) major shareholder Foresite Capital Management V, bought 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The shares…

閱讀原始碼

businesswire.com2026年7月29日

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines, today announced the publication of positive…

閱讀原始碼